Telomerase reverse transcriptase promoter mutations in bladder cancer: high frequency across stages, detection in urine, and lack of association with outcome.
about
Cancer-Specific Telomerase Reverse Transcriptase (TERT) Promoter Mutations: Biological and Clinical ImplicationsTranscription Regulation of the Human Telomerase Reverse Transcriptase (hTERT) GeneTelomerase: The Devil InsideRoles of telomeres and telomerase in cancer, and advances in telomerase-targeted therapiesReactivation of telomerase in cancerDistinct genetic alterations in small cell carcinoma from different anatomic sitesCancer. TERT promoter mutations and telomerase reactivation in urothelial cancer.The TERT promoter mutation incidence is modified by germline TERT rs2736098 and rs2736100 polymorphisms in hepatocellular carcinoma.TERT promoter mutations in renal cell carcinomas and upper tract urothelial carcinomas.The activating TERT promoter mutation C228T is recurrent in subsets of adrenal tumorsTelomere maintenance mechanisms in cancer: clinical implicationsHigh frequency of TERT promoter mutation in small cell carcinoma of bladder, but not in small cell carcinoma of other originsTERT promoter mutations are associated with distant metastases in upper tract urothelial carcinomas and serve as urinary biomarkers detected by a sensitive castPCRTERT promoter mutations and TERT mRNA but not FGFR3 mutations are urinary biomarkers in Han Chinese patients with urothelial bladder cancer.The UBC-40 Urothelial Bladder Cancer cell line index: a genomic resource for functional studies.A Potent Chemotherapeutic Strategy with Eg5 Inhibitor against Gemcitabine Resistant Bladder Cancer.Clinical Characteristics and Prognostic Significance of TERT Promoter Mutations in Cancer: A Cohort Study and a Meta-Analysis.Multiplex PCR and Next Generation Sequencing for the Non-Invasive Detection of Bladder CancerDetection of tumor-derived DNA in cerebrospinal fluid of patients with primary tumors of the brain and spinal cord.High prevalence of TERT promoter mutations in primary squamous cell carcinoma of the urinary bladder.Highly sensitive and specific novel biomarkers for the diagnosis of transitional bladder carcinoma.High prevalence of TERT promoter mutations in micropapillary urothelial carcinomaSpectrum of genetic mutations in de novo PUNLMP of the urinary bladder.The TERT promoter SNP rs2853669 decreases E2F1 transcription factor binding and increases mortality and recurrence risks in liver cancer.The genetic difference between Western and Chinese urothelial cell carcinomas: infrequent FGFR3 mutation in Han Chinese patients.Telomerase reverse transcriptase promotes cancer cell proliferation by augmenting tRNA expressionCirculating Biomarkers in Bladder Cancer.Urinary EpCAM in urothelial bladder cancer patients: characterisation and evaluation of biomarker potentialFrequent inactivating mutations of STAG2 in bladder cancer are associated with low tumour grade and stage and inversely related to chromosomal copy number changes.Detection of multiple mutations in urinary exfoliated cells from male bladder cancer patients at diagnosis and during follow-upNucleic acid-based biomarkers in body fluids of patients with urologic malignancies.Telomerase promoter mutations in cancer: an emerging molecular biomarker?Molecular biology of bladder cancer: new insights into pathogenesis and clinical diversity.Molecular markers in bladder cancer: Novel research frontiers.Beyond the exome: the role of non-coding somatic mutations in cancer.Centromere protein U is a potential target for gene therapy of human bladder cancer.Understanding TERT Promoter Mutations: A Common Path to Immortality.TERT promoter mutation status in sarcomatoid urothelial carcinomas of the upper urinary tract.Genetic Alterations in the Molecular Subtypes of Bladder Cancer: Illustration in the Cancer Genome Atlas Dataset.Urothelial Bladder Cancer Urinary Biomarkers.
P2860
Q54582656-AC28EE0A-E499-4F4A-AA8E-16B97465E7CDQ54605662-E7BF3E0F-578D-4DA9-92C3-101D86C545DDQ54605797-FAEF889F-5741-48E9-8E62-FC10FB84E045Q54605814-EFB23043-018E-4794-AAC8-2630CEFA70DFQ54605817-CCF36F0E-FEA3-4E7E-9D1B-6EBEE795CF3CQ54896502-7341B5F3-BA43-4B85-A44C-FE4B830EBB43Q54896699-818FD797-0759-41C6-9973-0E20D1D4E9C8Q54899036-F71D2A68-8E18-45B5-AE67-9283395E1377Q54899980-C70801F8-4091-4317-8CE7-4B72473A1764Q54902467-9876A4AB-8552-42E7-B98F-FDD45CEAE7C1Q54905462-60517D1D-260E-47A2-8A48-C31D05517294Q54905463-1291D289-0E2D-470C-A3E1-421736E22FD0Q54948399-DE4EDD04-9ECC-4D20-9989-D8A43D9EEE61Q54951347-6B7356F5-788E-4347-984D-109529DDFE66Q54951351-F544CB55-0A93-4E91-9C3A-816117C1D5B4Q54952320-41310094-A38C-41AC-9DCD-3B699D911683Q54971090-5C5AFAF0-9DCA-4987-9510-2D00BB7EB210Q54971204-4C9AF9F6-C871-4D52-9EAA-1982F5CB57A5Q54971207-A84BF9DE-33B7-4812-AC43-295D6C56FFC5Q54971454-E6E16ED8-0CD9-45EC-8EA8-8A1C1BC85DD8Q54971867-FA748AF7-E498-4A8D-9928-82E5D94E5812Q54990972-1FAF00A3-DB67-4BFD-8AC0-85BF1B0AE66AQ54990973-49CE0F08-01BA-43EE-B9AA-1CA4ABC96AA2Q54990976-D8FD4D86-01A4-4243-AF25-CBF63BFDA84BQ54990977-5ED19903-C721-4982-AC3C-F668030DA5FFQ54990978-C06CED78-1D0A-489F-A3FA-C1548E2B88ABQ54990986-95E40009-A3D4-43AB-BAC3-396FE679A48DQ54990987-1ADE9C6F-70E6-49B3-A762-C6628400FD18Q54990992-56D43593-0705-4D5B-BBC4-350B586FA4DBQ54990994-CC198560-A4E6-49F8-953C-02FDA755E4E8Q54990997-1426F806-8E62-4217-8B72-B4EBAFA71A25Q54993211-351704CF-EF51-49AD-9277-CC9DF98CF888
P1343
Q26738705-1CDA8184-6F53-4E5A-8F9F-DE8E2FE9C7D5Q26739925-451E1EC8-DF52-4BAB-AE49-A81888C57031Q26739948-FCD0C7C9-BE4A-4A80-8F53-5CC8A4E17CEFQ26744271-75CDB975-DA26-4E61-9679-58B41485ACDEQ26769014-EBF318B7-730D-4647-81E9-D7EC2802F4DEQ27008242-D32DEE82-CE03-4841-8020-F2E00D886551Q30459452-DAA2A7A8-4F4F-4701-AA95-31F67857825CQ33618591-A1CE2607-77D9-487B-A891-CE6AF3EA9CD8Q33688439-AD0990D1-389A-4F20-8288-424CF2CAE9D6Q33709979-31F59761-8367-4B7E-AD92-C23D2B0FE7FAQ34426966-453924A7-9A9F-4F38-83D1-E29A8B14B824Q34469034-505F5A58-D007-4DA9-8722-3EA2DBBC2ACBQ35068013-727F16CC-E1F4-4A00-8B54-741B5BFFF5E3Q35151119-5126D428-5BF1-4B9B-9639-B3AC0DEE0F13Q35638497-F91F749F-A219-4B76-BE45-3218A322ADA2Q35866655-E6D2FBFF-3220-47B0-B297-E0702B1B2693Q35901458-52C4C4C0-F8DE-4D5B-A0D6-4AB351878F93Q35930911-E2547FCE-F369-462F-8A11-E521A9DF98A8Q35946342-93BD0A93-3172-4759-861A-977B17E2DCEBQ35953342-1DAC6BD4-931D-4B56-8F67-C5ACAB8DEB3AQ35955378-D4DE9063-5FBD-4975-9C62-160DF4C7C522Q36103321-3D4E3416-06C4-4EE8-A7F3-61B1C87E4CA8Q36396486-5E8B602F-2A26-4083-B3DF-EE99B4A2620AQ36729504-5BFD7A0C-9190-4B99-BD97-946250225019Q37295512-37ADB462-39F3-4E0E-970E-B234D20A5A74Q37395716-5A20638F-DE8A-4A69-B92D-00D915E2EAB2Q37530401-71148729-FF21-49FB-9852-7BD97FE079D6Q37558983-1BCE119B-9173-4FE5-AF40-ECC28E05A9C0Q37649062-9AB8F99B-C251-42E4-B293-ED9F6F2955F4Q37687183-9B5032DF-AAFC-498D-B80F-034414F4B22AQ38216129-58B23876-34A0-4B2A-B1EE-52BB732BCC46Q38232447-0F44BF27-81A0-470B-9A6D-801A49B58ED4Q38297729-ADBB0278-59EC-4EE6-A2E3-788529348438Q38520403-6B0C7912-7778-40AF-9852-1EED1936ABFBQ38645015-D00BC6EF-99EA-46A7-89D4-144633FAA921Q38693334-E6E6DBA3-CB7F-4FF0-A9D1-8A6860245139Q38760235-5694E274-C0F5-4E1B-94DE-77CF2474637AQ38774845-37198CB8-8C4D-4345-AD77-A5B4D5B01A9EQ38862963-917E33D8-4A40-41AA-A477-CD59F7A5F56DQ38967481-ED0DC2F6-0228-493B-B4EF-67E9101DC36A
P2860
Telomerase reverse transcriptase promoter mutations in bladder cancer: high frequency across stages, detection in urine, and lack of association with outcome.
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
2013年论文
@zh
2013年论文
@zh-cn
name
Telomerase reverse transcripta ...... k of association with outcome.
@en
Telomerase reverse transcripta ...... k of association with outcome.
@nl
type
label
Telomerase reverse transcripta ...... k of association with outcome.
@en
Telomerase reverse transcripta ...... k of association with outcome.
@nl
prefLabel
Telomerase reverse transcripta ...... k of association with outcome.
@en
Telomerase reverse transcripta ...... k of association with outcome.
@nl
P2093
P4510
P50
P1433
P1476
Telomerase reverse transcripta ...... k of association with outcome.
@en
P2093
Alfredo Carrato
Ana Sagrera
Angela A G van Tilborg
Cheno Abas
Ellen C Zwarthoff
Irene Lurkin
Josep Lloreta
José A Lorente
Kirstin A van der Keur
Manolis Kogevinas
P304
P356
10.1016/J.EURURO.2013.08.052
P407
P50
P577
2013-09-07T00:00:00Z